Inhibrx Biosciences, Inc. (NASDAQ:INBX)
| Market Cap | 1.66B+281.4% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -138.18M+15.6% |
| EPS | -8.88+17.8% |
| Shares Out | 14.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | May 30, 2024 |
| Volume | 658,088 |
| Open | 119.85 |
| Previous Close | 114.34 |
| Day's Range | 112.05 - 128.54 |
| 52-Week Range | 26.19 - 155.29 |
| Beta | 3.67 |
| Analysts | Buy |
| Price Target | 285.00(+152.53%) |
| Earnings Date | Nov 13, 2026 |
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$INBX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in INBX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INBX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INBX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INBX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INBX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INBX
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $49.43M |
| VTIVanguard Morningstar Total Stock Market ETF | $30.33M |
| IWMiShares Russell 2000 ETF | $30.03M |
| IBBiShares Biotechnology ETF | $10.06M |
| FYCFirst Trust Small Cap Growth AlphaDEX Fund | $9.24M |
| VXFVanguard Extended Market ETF | $9.12M |
Estimated from each fund’s disclosed top holdings × AUM
INBX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from INBX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score